ID LYN_HUMAN Reviewed; 512 AA. AC P07948; A0AVQ5; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 3. DT 27-MAR-2024, entry version 260. DE RecName: Full=Tyrosine-protein kinase Lyn; DE EC=2.7.10.2; DE AltName: Full=Lck/Yes-related novel protein tyrosine kinase; DE AltName: Full=V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; DE AltName: Full=p53Lyn; DE AltName: Full=p56Lyn; GN Name=LYN; Synonyms=JTK8; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RX PubMed=3561390; DOI=10.1128/mcb.7.1.237-243.1987; RA Yamanashi Y., Fukushige S., Semba K., Sukegawa J., Miyajima N., RA Matsubara K., Yamamoto T., Toyoshima K.; RT "The yes-related cellular gene lyn encodes a possible tyrosine kinase RT similar to p56lck."; RL Mol. Cell. Biol. 7:237-243(1987). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING. RX PubMed=8125304; DOI=10.1016/0378-1119(94)90811-7; RA Rider L.G., Raben N., Miller L., Jelsema C.; RT "The cDNAs encoding two forms of the LYN protein tyrosine kinase are RT expressed in rat mast cells and human myeloid cells."; RL Gene 138:219-222(1994). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 369-424. RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 369-424. RX PubMed=1510669; DOI=10.1016/s0006-291x(05)81562-1; RA Bielke W., Ziemiecki A., Kappos L., Miescher G.C.; RT "Expression of the B cell-associated tyrosine kinase gene Lyn in primary RT neuroblastoma tumours and its modulation during the differentiation of RT neuroblastoma cell lines."; RL Biochem. Biophys. Res. Commun. 186:1403-1409(1992). RN [6] RP FUNCTION IN CD19 PHOSPHORYLATION, AND INTERACTION WITH CD19. RX PubMed=7687428; DOI=10.1006/bbrc.1993.1807; RA Roifman C.M., Ke S.; RT "CD19 is a substrate of the antigen receptor-associated protein tyrosine RT kinase in human B cells."; RL Biochem. Biophys. Res. Commun. 194:222-225(1993). RN [7] RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND INTERACTION WITH HCLS1. RX PubMed=7682714; DOI=10.1073/pnas.90.8.3631; RA Yamanashi Y., Okada M., Semba T., Yamori T., Umemori H., Tsunasawa S., RA Toyoshima K., Kitamura D., Watanabe T., Yamamoto T.; RT "Identification of HS1 protein as a major substrate of protein-tyrosine RT kinase(s) upon B-cell antigen receptor-mediated signaling."; RL Proc. Natl. Acad. Sci. U.S.A. 90:3631-3635(1993). RN [8] RP INTERACTION WITH FCGR1A, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND RP PHOSPHORYLATION. RX PubMed=8064233; DOI=10.1084/jem.180.3.1165; RA Wang A.V., Scholl P.R., Geha R.S.; RT "Physical and functional association of the high affinity immunoglobulin G RT receptor (Fc gamma RI) with the kinases Hck and Lyn."; RL J. Exp. Med. 180:1165-1170(1994). RN [9] RP PHOSPHORYLATION AT TYR-397 AND TYR-508, AND ACTIVITY REGULATION. RX PubMed=7935444; DOI=10.1128/mcb.14.11.7306-7313.1994; RA Hata A., Sabe H., Kurosaki T., Takata M., Hanafusa H.; RT "Functional analysis of Csk in signal transduction through the B-cell RT antigen receptor."; RL Mol. Cell. Biol. 14:7306-7313(1994). RN [10] RP INTERACTION WITH EPSTEIN-BARR VIRUS LMP2A (MICROBIAL INFECTION). RX PubMed=7895172; DOI=10.1016/s1074-7613(95)80040-9; RA Miller C.L., Burkhardt A.L., Lee J.H., Stealey B., Longnecker R., RA Bolen J.B., Kieff E.; RT "Integral membrane protein 2 of Epstein-Barr virus regulates reactivation RT from latency through dominant negative effects on protein-tyrosine RT kinases."; RL Immunity 2:155-166(1995). RN [11] RP PHOSPHORYLATION AT TYR-508 BY MATK. RC TISSUE=Platelet; RX PubMed=9171348; DOI=10.1093/emboj/16.9.2342; RA Hirao A., Hamaguchi I., Suda T., Yamaguchi N.; RT "Translocation of the Csk homologous kinase (Chk/Hyl) controls activity of RT CD36-anchored Lyn tyrosine kinase in thrombin-stimulated platelets."; RL EMBO J. 16:2342-2351(1997). RN [12] RP FUNCTION, INTERACTION WITH NEDD9 AND BCAR1, AND PHOSPHORYLATION. RX PubMed=9020138; DOI=10.1074/jbc.272.7.4230; RA Manie S.N., Beck A.R.P., Astier A., Law S.F., Canty T., Hirai H., RA Druker B.J., Avraham H., Haghayeghi N., Sattler M., Salgia R., RA Griffin J.D., Golemis E.A., Freedman A.S.; RT "Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, RT in a cytoskeleton-dependent signaling pathway initiated by ligation of RT integrin or antigen receptor on human B cells."; RL J. Biol. Chem. 272:4230-4236(1997). RN [13] RP INTERACTION WITH FCGR2B. RX PubMed=9232445; DOI=10.1016/s0165-2478(97)00055-2; RA Sarmay G., Koncz G., Pecht I., Gergely J.; RT "Fc gamma receptor type IIb induced recruitment of inositol and protein RT phosphatases to the signal transductory complex of human B-cell."; RL Immunol. Lett. 57:159-164(1997). RN [14] RP INTERACTION WITH KIT, AND PHOSPHORYLATION. RX PubMed=9341198; DOI=10.1074/jbc.272.43.27450; RA Linnekin D., DeBerry C.S., Mou S.; RT "Lyn associates with the juxtamembrane region of c-Kit and is activated by RT stem cell factor in hematopoietic cell lines and normal progenitor cells."; RL J. Biol. Chem. 272:27450-27455(1997). RN [15] RP FUNCTION IN DNA DAMAGE RESPONSE; APOPTOSIS AND PHOSPHORYLATION OF RP PTPN6/SHPTP1, AND INTERACTION WITH PTPN6/SHPTP1. RX PubMed=10574931; DOI=10.1074/jbc.274.49.34663; RA Yoshida K., Kharbanda S., Kufe D.; RT "Functional interaction between SHPTP1 and the Lyn tyrosine kinase in the RT apoptotic response to DNA damage."; RL J. Biol. Chem. 274:34663-34668(1999). RN [16] RP INTERACTION WITH CBLC. RX PubMed=10362357; DOI=10.1038/sj.onc.1202753; RA Keane M.M., Ettenberg S.A., Nau M.M., Banerjee P., Cuello M., Penninger J., RA Lipkowitz S.; RT "cbl-3: a new mammalian cbl family protein."; RL Oncogene 18:3365-3375(1999). RN [17] RP FUNCTION IN CD79A PHOSPHORYLATION, AND INTERACTION WITH CD79A. RX PubMed=10748115; DOI=10.1074/jbc.m909044199; RA Gaul B.S., Harrison M.L., Geahlen R.L., Burton R.A., Post C.B.; RT "Substrate recognition by the Lyn protein-tyrosine kinase. NMR structure of RT the immunoreceptor tyrosine-based activation motif signaling region of the RT B cell antigen receptor."; RL J. Biol. Chem. 275:16174-16182(2000). RN [18] RP FUNCTION IN REGULATION OF MAST CELL PROLIFERATION, AND MUTAGENESIS OF RP LYS-275. RX PubMed=11435302; DOI=10.1182/blood.v98.2.343; RA O'Laughlin-Bunner B., Radosevic N., Taylor M.L., Shivakrupa R., DeBerry C., RA Metcalfe D.D., Zhou M., Lowell C., Linnekin D.; RT "Lyn is required for normal stem cell factor-induced proliferation and RT chemotaxis of primary hematopoietic cells."; RL Blood 98:343-350(2001). RN [19] RP INTERACTION WITH PDE4A. RC TISSUE=Brain; RX PubMed=11306681; DOI=10.1124/mol.59.5.996; RA Rena G., Begg F., Ross A., MacKenzie C., McPhee I., Campbell L., Huston E., RA Sullivan M., Houslay M.D.; RT "Molecular cloning, genomic positioning, promoter identification, and RT characterization of the novel cyclic AMP-specific phosphodiesterase RT PDE4A10."; RL Mol. Pharmacol. 59:996-1011(2001). RN [20] RP FUNCTION. RX PubMed=10891478; DOI=10.1128/mcb.20.15.5370-5380.2000; RA Yoshida K., Weichselbaum R., Kharbanda S., Kufe D.; RT "Role for Lyn tyrosine kinase as a regulator of stress-activated protein RT kinase activity in response to DNA damage."; RL Mol. Cell. Biol. 20:5370-5380(2000). RN [21] RP FUNCTION IN DNA DAMAGE RESPONSE; APOPTOSIS AND PHOSPHORYLATION OF PPP1R15A, RP INTERACTION WITH PPP1R15A, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-275. RX PubMed=11517336; DOI=10.1073/pnas.191130798; RA Grishin A.V., Azhipa O., Semenov I., Corey S.J.; RT "Interaction between growth arrest-DNA damage protein 34 and Src kinase Lyn RT negatively regulates genotoxic apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 98:10172-10177(2001). RN [22] RP FUNCTION IN PHOSPHORYLATION OF KIT AND DOK1, CATALYTIC ACTIVITY, AND RP INTERACTION WITH KIT. RX PubMed=11825908; DOI=10.1074/jbc.m200277200; RA Liang X., Wisniewski D., Strife A., Shivakrupa R., Clarkson B., Resh M.D.; RT "Phosphatidylinositol 3-kinase and Src family kinases are required for RT phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling."; RL J. Biol. Chem. 277:13732-13738(2002). RN [23] RP INTERACTION WITH MUC1. RX PubMed=12750561; DOI=10.4161/cbt.2.2.282; RA Li Y., Chen W., Ren J., Yu W.H., Li Q., Yoshida K., Kufe D.; RT "DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin- RT 7."; RL Cancer Biol. Ther. 2:187-193(2003). RN [24] RP INTERACTION WITH UNC119. RX PubMed=12496276; DOI=10.1074/jbc.m208261200; RA Cen O., Gorska M.M., Stafford S.J., Sur S., Alam R.; RT "Identification of UNC119 as a novel activator of SRC-type tyrosine RT kinases."; RL J. Biol. Chem. 278:8837-8845(2003). RN [25] RP FUNCTION IN THPO-MEDIATED CELL PROLIFERATION. RX PubMed=14726379; DOI=10.1182/blood-2003-10-3566; RA Lannutti B.J., Drachman J.G.; RT "Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of RT hematopoietic cell lines and primary megakaryocytic progenitors."; RL Blood 103:3736-3743(2004). RN [26] RP SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF LYS-275; ASP-346; GLU-353; RP ASP-498 AND ASP-499. RX PubMed=15173188; DOI=10.1083/jcb.200403011; RA Kasahara K., Nakayama Y., Ikeda K., Fukushima Y., Matsuda D., Horimoto S., RA Yamaguchi N.; RT "Trafficking of Lyn through the Golgi caveolin involves the charged RT residues on alphaE and alphaI helices in the kinase domain."; RL J. Cell Biol. 165:641-652(2004). RN [27] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055; RA Roskoski R. Jr.; RT "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor."; RL Biochem. Biophys. Res. Commun. 337:1-13(2005). RN [28] RP FUNCTION IN PHOSPHORYLATION OF HCLS1. RX PubMed=15795233; DOI=10.1074/jbc.m412634200; RA Brunati A.M., Deana R., Folda A., Massimino M.L., Marin O., Ledro S., RA Pinna L.A., Donella-Deana A.; RT "Thrombin-induced tyrosine phosphorylation of HS1 in human platelets is RT sequentially catalyzed by Syk and Lyn tyrosine kinases and associated with RT the cellular migration of the protein."; RL J. Biol. Chem. 280:21029-21035(2005). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-508, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [30] RP FUNCTION. RX PubMed=16467205; DOI=10.1182/blood-2005-08-3343; RA Nakata Y., Tomkowicz B., Gewirtz A.M., Ptasznik A.; RT "Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine RT receptors in normal human CD34+ marrow cells."; RL Blood 107:4234-4239(2006). RN [31] RP INTERACTION WITH ABL1. RX PubMed=16912036; DOI=10.1074/jbc.m605902200; RA Meyn M.A. III, Wilson M.B., Abdi F.A., Fahey N., Schiavone A.P., Wu J., RA Hochrein J.M., Engen J.R., Smithgall T.E.; RT "Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate RT Bcr-Abl transforming activity."; RL J. Biol. Chem. 281:30907-30916(2006). RN [32] RP INTERACTION WITH PAG1, MUTAGENESIS OF TYR-397, CHARACTERIZATION OF VARIANT RP SAIDV PHE-508, ACTIVITY REGULATION, AND UBIQUITINATION. RX PubMed=16920712; DOI=10.1074/jbc.m602637200; RA Ingley E., Schneider J.R., Payne C.J., McCarthy D.J., Harder K.W., RA Hibbs M.L., Klinken S.P.; RT "Csk-binding protein mediates sequential enzymatic down-regulation and RT degradation of Lyn in erythropoietin-stimulated cells."; RL J. Biol. Chem. 281:31920-31929(2006). RN [33] RP INTERACTION WITH TGFB1I1. RX PubMed=17233630; DOI=10.1042/bj20061618; RA Rathore V.B., Okada M., Newman P.J., Newman D.K.; RT "Paxillin family members function as Csk-binding proteins that regulate Lyn RT activity in human and murine platelets."; RL Biochem. J. 403:275-281(2007). RN [34] RP FUNCTION IN PHOSPHORYLATION OF LPXN, AND INTERACTION WITH LPXN. RX PubMed=17640867; DOI=10.1074/jbc.m704625200; RA Chew V., Lam K.P.; RT "Leupaxin negatively regulates B cell receptor signaling."; RL J. Biol. Chem. 282:27181-27191(2007). RN [35] RP INTERACTION WITH TOM1L1, AND FUNCTION IN TOM1L1 PHOSPHORYLATION. RX PubMed=17977829; DOI=10.1074/jbc.m705168200; RA Zhang J., Suzuki K., Hitomi T., Siraganian R.P.; RT "TOM1L1 is a Lyn substrate involved in FcepsilonRI signaling in mast RT cells."; RL J. Biol. Chem. 282:37669-37677(2007). RN [36] RP FUNCTION IN CELL PROLIFERATION AND SURVIVAL, PHOSPHORYLATION, SUBCELLULAR RP LOCATION, AND ROLE IN DISEASE. RX PubMed=18056483; DOI=10.1182/blood-2007-04-082099; RA Dos Santos C., Demur C., Bardet V., Prade-Houdellier N., Payrastre B., RA Recher C.; RT "A critical role for Lyn in acute myeloid leukemia."; RL Blood 111:2269-2279(2008). RN [37] RP FUNCTION, PHOSPHORYLATION AT TYR-397 AND TYR-508, INTERACTION WITH PAG1 AND RP STAT3, AND SUBCELLULAR LOCATION. RX PubMed=18070987; DOI=10.1182/blood-2007-05-090985; RA Tauzin S., Ding H., Khatib K., Ahmad I., Burdevet D., RA van Echten-Deckert G., Lindquist J.A., Schraven B., Din N.U., Borisch B., RA Hoessli D.C.; RT "Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine RT kinase in human B-NHL rafts."; RL Blood 111:2310-2320(2008). RN [38] RP INTERACTION WITH CBL AND BCR-ABL, FUNCTION IN PHOSPHORYLATION OF BCR-ABL, RP AND ROLE IN DISEASE. RX PubMed=18235045; DOI=10.1182/blood-2007-08-109330; RA Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., Talpaz M., RA Donato N.J.; RT "Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein RT stability in imatinib-resistant chronic myelogenous leukemia cells."; RL Blood 111:3821-3829(2008). RN [39] RP SUBCELLULAR LOCATION, MYRISTOYLATION AT GLY-2, PALMITOYLATION AT CYS-3, AND RP MUTAGENESIS OF GLY-2; CYS-3 AND LYS-275. RX PubMed=18817770; DOI=10.1016/j.yexcr.2008.08.019; RA Ikeda K., Nakayama Y., Togashi Y., Obata Y., Kuga T., Kasahara K., RA Fukumoto Y., Yamaguchi N.; RT "Nuclear localization of Lyn tyrosine kinase mediated by inhibition of its RT kinase activity."; RL Exp. Cell Res. 314:3392-3404(2008). RN [40] RP FUNCTION IN ADHESION AND CELL MIGRATION. RX PubMed=18802065; DOI=10.4049/jimmunol.181.7.4632; RA Malik M., Chen Y.-Y., Kienzle M.F., Tomkowicz B.E., Collman R.G., RA Ptasznik A.; RT "Monocyte migration and LFA-1-mediated attachment to brain microvascular RT endothelia is regulated by SDF-1 alpha through Lyn kinase."; RL J. Immunol. 181:4632-4637(2008). RN [41] RP PHOSPHORYLATION AT TYR-193 AND TYR-460, AND ROLE IN DISEASE. RX PubMed=18577747; DOI=10.1093/jnci/djn188; RA Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G., Darnay B.G., RA Lamothe B., Sun H., Talpaz M., Donato N.J.; RT "Association between imatinib-resistant BCR-ABL mutation-negative leukemia RT and persistent activation of LYN kinase."; RL J. Natl. Cancer Inst. 100:926-939(2008). RN [42] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [43] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-13; TYR-473 AND RP TYR-508, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [44] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [45] RP INTERACTION WITH FASLG. RX PubMed=19807924; DOI=10.1186/1471-2172-10-53; RA Voss M., Lettau M., Janssen O.; RT "Identification of SH3 domain interaction partners of human FasL (CD178) by RT phage display screening."; RL BMC Immunol. 10:53-53(2009). RN [46] RP INTERACTION WITH ADAM15. RX PubMed=19718658; DOI=10.1002/jcb.22317; RA Kleino I., Ortiz R.M., Yritys M., Huovila A.P., Saksela K.; RT "Alternative splicing of ADAM15 regulates its interactions with cellular RT SH3 proteins."; RL J. Cell. Biochem. 108:877-885(2009). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-13; SER-228; TYR-306; RP TYR-316; TYR-473 AND TYR-508, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [48] RP FUNCTION IN LTR4 AND LTR6 HETERODIMERIZATION, AND INTERACTION WITH CD36. RX PubMed=20037584; DOI=10.1038/ni.1836; RA Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., RA Rayner K.J., Boyer L., Zhong R., Frazier W.A., Lacy-Hulbert A., RA El Khoury J., Golenbock D.T., Moore K.J.; RT "CD36 ligands promote sterile inflammation through assembly of a Toll-like RT receptor 4 and 6 heterodimer."; RL Nat. Immunol. 11:155-161(2010). RN [49] RP INTERACTION WITH NDFIP1 AND NDFIP2, AND UBIQUITINATION. RX PubMed=20534535; DOI=10.1073/pnas.0911714107; RA Mund T., Pelham H.R.; RT "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin RT ligase activators Ndfip1 and Ndfip2."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010). RN [50] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [51] RP INTERACTION WITH SCIMP. RX PubMed=21930792; DOI=10.1128/mcb.05817-11; RA Draber P., Vonkova I., Stepanek O., Hrdinka M., Kucova M., Skopcova T., RA Otahal P., Angelisova P., Horejsi V., Yeung M., Weiss A., Brdicka T.; RT "SCIMP, a transmembrane adapter protein involved in major RT histocompatibility complex class II signaling."; RL Mol. Cell. Biol. 31:4550-4562(2011). RN [52] RP REVIEW. RX PubMed=15220000; DOI=10.1016/j.molimm.2004.04.010; RA Lowell C.A.; RT "Src-family kinases: rheostats of immune cell signaling."; RL Mol. Immunol. 41:631-643(2004). RN [53] RP REVIEW ON ROLE IN B CELLS. RX PubMed=15489917; DOI=10.1038/sj.onc.1208075; RA Gauld S.B., Cambier J.C.; RT "Src-family kinases in B-cell development and signaling."; RL Oncogene 23:8001-8006(2004). RN [54] RP REVIEW ON ROLE IN B CELLS. RX PubMed=15664155; DOI=10.1016/j.immuni.2004.12.004; RA Xu Y., Harder K.W., Huntington N.D., Hibbs M.L., Tarlinton D.M.; RT "Lyn tyrosine kinase: accentuating the positive and the negative."; RL Immunity 22:9-18(2005). RN [55] RP REVIEW ON ROLE IN GROWTH FACTOR SIGNALING. RX PubMed=16801133; DOI=10.1080/08977190600581327; RA Hibbs M.L., Harder K.W.; RT "The duplicitous nature of the Lyn tyrosine kinase in growth factor RT signaling."; RL Growth Factors 24:137-149(2006). RN [56] RP REVIEW ON ROLE IN MAST CELLS. RX PubMed=18772004; DOI=10.1016/s0065-2776(08)00403-3; RA Rivera J., Fierro N.A., Olivera A., Suzuki R.; RT "New insights on mast cell activation via the high affinity receptor for RT IgE."; RL Adv. Immunol. 98:85-120(2008). RN [57] RP ROLE IN MYELOID CELL FUNCTION, AND SIGNALING. RX PubMed=19290919; DOI=10.1111/j.1600-065x.2008.00758.x; RA Scapini P., Pereira S., Zhang H., Lowell C.A.; RT "Multiple roles of Lyn kinase in myeloid cell signaling and function."; RL Immunol. Rev. 228:23-40(2009). RN [58] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [59] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [60] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [61] RP MYRISTOYLATION AT GLY-2, CLEAVAGE OF INITIATOR METHIONINE, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=25255805; DOI=10.1038/ncomms5919; RA Thinon E., Serwa R.A., Broncel M., Brannigan J.A., Brassat U., Wright M.H., RA Heal W.P., Wilkinson A.J., Mann D.J., Tate E.W.; RT "Global profiling of co- and post-translationally N-myristoylated proteomes RT in human cells."; RL Nat. Commun. 5:4919-4919(2014). RN [62] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [63] RP STRUCTURE BY NMR OF 61-123 IN COMPLEX WITH SAIMIRIINE HERPESVIRUS 2 RP TYROSINE KINASE INTERACTING PROTEIN (MICROBIAL INFECTION). RX PubMed=11955060; DOI=10.1021/bi015986j; RA Schweimer K., Hoffmann S., Bauer F., Friedrich U., Kardinal C., RA Feller S.M., Biesinger B., Sticht H.; RT "Structural investigation of the binding of a herpesviral protein to the RT SH3 domain of tyrosine kinase Lck."; RL Biochemistry 41:5120-5130(2002). RN [64] RP STRUCTURE BY NMR OF 61-122, AND INTERACTION WITH HERPESVIRUS TYROSINE RP KINASE INTERACTING PROTEIN (MICROBIAL INFECTION). RX PubMed=16155203; DOI=10.1110/ps.051563605; RA Bauer F., Schweimer K., Meiselbach H., Hoffmann S., Rosch P., Sticht H.; RT "Structural characterization of Lyn-SH3 domain in complex with a RT herpesviral protein reveals an extended recognition motif that enhances RT binding affinity."; RL Protein Sci. 14:2487-2498(2005). RN [65] RP X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 233-512 IN COMPLEX WITH RP STAUROSPORINE. RX PubMed=19857964; DOI=10.1016/j.bmcl.2009.10.038; RA Miyano N., Kinoshita T., Nakai R., Kirii Y., Yokota K., Tada T.; RT "Structural basis for the inhibitor recognition of human Lyn kinase RT domain."; RL Bioorg. Med. Chem. Lett. 19:6557-6560(2009). RN [66] RP VARIANT [LARGE SCALE ANALYSIS] TYR-385. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [67] RP INVOLVEMENT IN SAIDV, AND VARIANT SAIDV 508-TYR--PRO-512 DEL. RX DOI=10.1186/1546-0096-12-S1-O25; RA De Jesus A.A., Montealegre G., Liu Y., Marrero B., Kuehn H., Calvo K., RA Rosenzweig S., Fleisher T., Chyi-Chia Lee R., Brundidge A., Chapelle D., RA Huang Y., Brooks S., Moir S., Meffre E., Merchant M., Deng Z., RA Goldbach-Mansky R.; RT "A de novo nonsense mutation in the tyrosine kinase lyn in a patient with RT an early onset autoinflammatory phenotype."; RL Pediatr. Rheumatol. Online J. 12:O25-O25(2014). RN [68] RP VARIANT SAIDV HIS-508, CHARACTERIZATION OF VARIANTS SAIDV 508-TYR--PRO-512 RP DEL; HIS-508 AND PHE-508, AND FUNCTION. RX PubMed=36122175; DOI=10.1002/art.42354; RA Louvrier C., El Khouri E., Grall Lerosey M., Quartier P., Guerrot A.M., RA Bader Meunier B., Chican J., Mohammad M., Assrawi E., Daskalopoulou A., RA Arenas Garcia A., Copin B., Piterboth W., Dastot Le Moal F., Karabina S.A., RA Amselem S., Giurgea I.; RT "De Novo Gain-Of-Function Variations in LYN Associated With an Early-Onset RT Systemic Autoinflammatory Disorder."; RL Arthritis Rheumatol. 75:468-474(2023). RN [69] RP VARIANTS SAIDV 507-GLN--PRO-512 DEL; 508-TYR--PRO-512 DEL AND PHE-508, RP CHARACTERIZATION OF VARIANTS SAIDV 507-GLN--PRO-512 DEL; 508-TYR--PRO-512 RP DEL AND PHE-508, AND FUNCTION. RX PubMed=36932076; DOI=10.1038/s41467-023-36941-y; RA de Jesus A.A., Chen G., Yang D., Brdicka T., Ruth N.M., Bennin D., RA Cebecauerova D., Malcova H., Freeman H., Martin N., Svojgr K., Passo M.H., RA Bhuyan F., Alehashemi S., Rastegar A.T., Uss K., Kardava L., Marrero B., RA Duric I., Omoyinmi E., Peldova P., Lee C.R., Kleiner D.E., Hadigan C.M., RA Hewitt S.M., Pittaluga S., Carmona-Rivera C., Calvo K.R., Shah N., RA Balascakova M., Fink D.L., Kotalova R., Parackova Z., Peterkova L., RA Kuzilkova D., Campr V., Sramkova L., Biancotto A., Brooks S.R., Manes C., RA Meffre E., Harper R.L., Kuehn H., Kaplan M.J., Brogan P., Rosenzweig S.D., RA Merchant M., Deng Z., Huttenlocher A., Moir S.L., Kuhns D.B., Boehm M., RA Skvarova Kramarzova K., Goldbach-Mansky R.; RT "Constitutively active Lyn kinase causes a cutaneous small vessel RT vasculitis and liver fibrosis syndrome."; RL Nat. Commun. 14:1502-1502(2023). CC -!- FUNCTION: Non-receptor tyrosine-protein kinase that transmits signals CC from cell surface receptors and plays an important role in the CC regulation of innate and adaptive immune responses, hematopoiesis, CC responses to growth factors and cytokines, integrin signaling, but also CC responses to DNA damage and genotoxic agents. Functions primarily as CC negative regulator, but can also function as activator, depending on CC the context. Required for the initiation of the B-cell response, but CC also for its down-regulation and termination. Plays an important role CC in the regulation of B-cell differentiation, proliferation, survival CC and apoptosis, and is important for immune self-tolerance. Acts CC downstream of several immune receptors, including the B-cell receptor, CC CD79A, CD79B, CD5, CD19, CD22, FCER1, FCGR2, FCGR1A, TLR2 and TLR4. CC Plays a role in the inflammatory response to bacterial CC lipopolysaccharide. Mediates the responses to cytokines and growth CC factors in hematopoietic progenitors, platelets, erythrocytes, and in CC mature myeloid cells, such as dendritic cells, neutrophils and CC eosinophils. Acts downstream of EPOR, KIT, MPL, the chemokine receptor CC CXCR4, as well as the receptors for IL3, IL5 and CSF2. Plays an CC important role in integrin signaling. Regulates cell proliferation, CC survival, differentiation, migration, adhesion, degranulation, and CC cytokine release. Involved in the regulation of endothelial activation, CC neutrophil adhesion and transendothelial migration (PubMed:36932076). CC Down-regulates signaling pathways by phosphorylation of immunoreceptor CC tyrosine-based inhibitory motifs (ITIM), that then serve as binding CC sites for phosphatases, such as PTPN6/SHP-1, PTPN11/SHP-2 and CC INPP5D/SHIP-1, that modulate signaling by dephosphorylation of kinases CC and their substrates. Phosphorylates LIME1 in response to CD22 CC activation. Phosphorylates BTK, CBL, CD5, CD19, CD72, CD79A, CD79B, CC CSF2RB, DOK1, HCLS1, LILRB3/PIR-B, MS4A2/FCER1B, SYK and TEC. Promotes CC phosphorylation of SIRPA, PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1. CC Mediates phosphorylation of the BCR-ABL fusion protein. Required for CC rapid phosphorylation of FER in response to FCER1 activation. Mediates CC KIT phosphorylation. Acts as an effector of EPOR (erythropoietin CC receptor) in controlling KIT expression and may play a role in CC erythroid differentiation during the switch between proliferation and CC maturation. Depending on the context, activates or inhibits several CC signaling cascades. Regulates phosphatidylinositol 3-kinase activity CC and AKT1 activation. Regulates activation of the MAP kinase signaling CC cascade, including activation of MAP2K1/MEK1, MAPK1/ERK2, MAPK3/ERK1, CC MAPK8/JNK1 and MAPK9/JNK2. Mediates activation of STAT5A and/or STAT5B. CC Phosphorylates LPXN on 'Tyr-72'. Kinase activity facilitates TLR4-TLR6 CC heterodimerization and signal initiation. Phosphorylates SCIMP on 'Tyr- CC 107'; this enhances binding of SCIMP to TLR4, promoting the CC phosphorylation of TLR4, and a selective cytokine response to CC lipopolysaccharide in macrophages (By similarity). Phosphorylates CLNK CC (By similarity). Phosphorylates BCAR1/CAS and NEDD9/HEF1 CC (PubMed:9020138). {ECO:0000250|UniProtKB:P25911, CC ECO:0000269|PubMed:10574931, ECO:0000269|PubMed:10748115, CC ECO:0000269|PubMed:10891478, ECO:0000269|PubMed:11435302, CC ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:11825908, CC ECO:0000269|PubMed:14726379, ECO:0000269|PubMed:15795233, CC ECO:0000269|PubMed:16467205, ECO:0000269|PubMed:17640867, CC ECO:0000269|PubMed:17977829, ECO:0000269|PubMed:18056483, CC ECO:0000269|PubMed:18070987, ECO:0000269|PubMed:18235045, CC ECO:0000269|PubMed:18577747, ECO:0000269|PubMed:18802065, CC ECO:0000269|PubMed:19290919, ECO:0000269|PubMed:20037584, CC ECO:0000269|PubMed:36122175, ECO:0000269|PubMed:36932076, CC ECO:0000269|PubMed:7687428, ECO:0000269|PubMed:9020138}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl- CC [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:11825908, CC ECO:0000269|PubMed:7682714, ECO:0000269|PubMed:8064233}; CC -!- ACTIVITY REGULATION: Subject to autoinhibition, mediated by CC intramolecular interactions between the SH2 domain and the C-terminal CC phosphotyrosine. Phosphorylation at Tyr-397 is required for optimal CC activity. Phosphorylated by CSK at Tyr-508; phosphorylation at Tyr-508 CC inhibits kinase activity. Kinase activity is modulated by CC dephosphorylation by PTPRC/CD45. Inhibited by Dasatinib, PP2, and CC SU6656. {ECO:0000269|PubMed:16920712, ECO:0000269|PubMed:7935444}. CC -!- SUBUNIT: Interacts with TEC. Interacts (via SH2 domain) with FLT3 CC (tyrosine phosphorylated). Interacts with LIME1 and with CD79A upon CC activation of the B-cell antigen receptor. Interacts with the B-cell CC receptor complex. Interacts with phosphorylated THEMIS2. Interacts with CC EPOR. Interacts with MS4A2/FCER1B. Interaction (via the SH2 and SH3 CC domains) with MUC1 is stimulated by IL7 and the subsequent CC phosphorylation increases the binding between MUC1 and CTNNB1/beta- CC catenin. Interacts with ADAM15. Interacts with NDFIP2 and more weakly CC with NDFIP1. Interacts with FASLG. Interacts with KIT. Interacts with CC HCLS1. Interacts with FCGR2B. Interacts with FCGR1A; the interaction CC may be indirect. Interacts with CD19, CD22, CD79A and CD79B. Interacts CC (via SH3 domain) with CBLC, PPP1R15A and PDE4A. Interacts with TGFB1I1. CC Interacts (via SH3 domain) with PIK3R1, the regulatory subunit of CC phosphatidylinositol 3-kinase; this interaction enhances CC phosphatidylinositol 3-kinase activity. Interacts with CSF2RB, the CC common subunit of the IL3, IL5 and CSF2 receptors. Interacts with PAG1; CC identified in a complex with PAG1 and STAT3. Interacts with ABL1. CC Interacts with PTPN6/SHP-1. Interacts (via SH3 domain) with SCIMP (via CC proline-rich region) (PubMed:21930792). This interaction facilitates CC the phosphorylation of SCIMP on 'Tyr-107', which enhances binding of CC SCIMP to TLR4, and consequently the phosphorylation of TLR4 in response CC to stimulation by lipopolysaccharide in macrophages (By similarity). CC Interacts with LPXN (via LD motif 3) and the interaction is induced CC upon B-cell antigen receptor (BCR) activation. Interacts (via SH3- CC domain) with ANKRD54 (via ankyrin repeat region) in an activation- CC independent status of LYN. Forms a multiprotein complex with ANKRD54 CC and HCLS1. Interacts (via SH2 and SH3 domains) with UNC119; leading to CC LYN activation. Interacts with CD36. Interacts with LYN (By CC similarity). Interacts with SKAP1 and FYB1; this interaction promotes CC the phosphorylation of CLNK (By similarity). Interacts with BCAR1/CAS CC and NEDD9/HEF1 (PubMed:9020138). {ECO:0000250|UniProtKB:P25911, CC ECO:0000269|PubMed:10362357, ECO:0000269|PubMed:10574931, CC ECO:0000269|PubMed:10748115, ECO:0000269|PubMed:11306681, CC ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:11825908, CC ECO:0000269|PubMed:12496276, ECO:0000269|PubMed:12750561, CC ECO:0000269|PubMed:16912036, ECO:0000269|PubMed:16920712, CC ECO:0000269|PubMed:17233630, ECO:0000269|PubMed:17640867, CC ECO:0000269|PubMed:17977829, ECO:0000269|PubMed:18070987, CC ECO:0000269|PubMed:18235045, ECO:0000269|PubMed:19718658, CC ECO:0000269|PubMed:19807924, ECO:0000269|PubMed:19857964, CC ECO:0000269|PubMed:20037584, ECO:0000269|PubMed:20534535, CC ECO:0000269|PubMed:21930792, ECO:0000269|PubMed:7682714, CC ECO:0000269|PubMed:7687428, ECO:0000269|PubMed:8064233, CC ECO:0000269|PubMed:9020138, ECO:0000269|PubMed:9232445, CC ECO:0000269|PubMed:9341198}. CC -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus LMP2A. CC {ECO:0000269|PubMed:7895172}. CC -!- SUBUNIT: (Microbial infection) Interacts with Herpes virus saimiri CC tyrosine kinase interacting protein (Tip). CC {ECO:0000269|PubMed:11955060, ECO:0000269|PubMed:16155203}. CC -!- INTERACTION: CC P07948; P01023: A2M; NbExp=3; IntAct=EBI-79452, EBI-640741; CC P07948; O43184: ADAM12; NbExp=2; IntAct=EBI-79452, EBI-2625825; CC P07948; Q13444: ADAM15; NbExp=2; IntAct=EBI-79452, EBI-77818; CC P07948; P05067: APP; NbExp=3; IntAct=EBI-79452, EBI-77613; CC P07948; P10275: AR; NbExp=5; IntAct=EBI-79452, EBI-608057; CC P07948; Q8NDB2: BANK1; NbExp=3; IntAct=EBI-79452, EBI-2837677; CC P07948; Q96GW7: BCAN; NbExp=3; IntAct=EBI-79452, EBI-2690445; CC P07948; P20273: CD22; NbExp=2; IntAct=EBI-79452, EBI-78277; CC P07948; P25063: CD24; NbExp=6; IntAct=EBI-79452, EBI-6267018; CC P07948; P16671: CD36; NbExp=3; IntAct=EBI-79452, EBI-2808214; CC P07948; P11049: CD37; NbExp=5; IntAct=EBI-79452, EBI-6139068; CC P07948; P46527: CDKN1B; NbExp=2; IntAct=EBI-79452, EBI-519280; CC P07948; P50570-2: DNM2; NbExp=3; IntAct=EBI-79452, EBI-10968534; CC P07948; P00533: EGFR; NbExp=7; IntAct=EBI-79452, EBI-297353; CC P07948; Q9BS26: ERP44; NbExp=3; IntAct=EBI-79452, EBI-541644; CC P07948; Q13480: GAB1; NbExp=7; IntAct=EBI-79452, EBI-517684; CC P07948; Q9HCN6: GP6; NbExp=5; IntAct=EBI-79452, EBI-515278; CC P07948; Q9HCN6-1: GP6; NbExp=2; IntAct=EBI-79452, EBI-15816577; CC P07948; P08238: HSP90AB1; NbExp=2; IntAct=EBI-79452, EBI-352572; CC P07948; P05556: ITGB1; NbExp=4; IntAct=EBI-79452, EBI-703066; CC P07948; P10721: KIT; NbExp=7; IntAct=EBI-79452, EBI-1379503; CC P07948; Q96L34: MARK4; NbExp=3; IntAct=EBI-79452, EBI-302319; CC P07948; P33993: MCM7; NbExp=4; IntAct=EBI-79452, EBI-355924; CC P07948; P51608: MECP2; NbExp=3; IntAct=EBI-79452, EBI-1189067; CC P07948; P08581: MET; NbExp=2; IntAct=EBI-79452, EBI-1039152; CC P07948; Q9NWQ8: PAG1; NbExp=16; IntAct=EBI-79452, EBI-2828115; CC P07948; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-79452, EBI-9090282; CC P07948; P07602: PSAP; NbExp=3; IntAct=EBI-79452, EBI-716699; CC P07948; P63244: RACK1; NbExp=2; IntAct=EBI-79452, EBI-296739; CC P07948; Q6UWF3: SCIMP; NbExp=3; IntAct=EBI-79452, EBI-2872510; CC P07948; P37840: SNCA; NbExp=3; IntAct=EBI-79452, EBI-985879; CC P07948; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-79452, EBI-5235340; CC P07948; P12931: SRC; NbExp=4; IntAct=EBI-79452, EBI-621482; CC P07948; Q8R5G7: Arap3; Xeno; NbExp=2; IntAct=EBI-79452, EBI-621463; CC P07948; Q08857: Cd36; Xeno; NbExp=2; IntAct=EBI-79452, EBI-8346984; CC P07948; O92972; Xeno; NbExp=2; IntAct=EBI-79452, EBI-710506; CC P07948; P22575; Xeno; NbExp=3; IntAct=EBI-79452, EBI-866709; CC P07948; P27958; Xeno; NbExp=4; IntAct=EBI-79452, EBI-706378; CC P07948; Q9WMX2; Xeno; NbExp=3; IntAct=EBI-79452, EBI-710918; CC P07948-1; P00533: EGFR; NbExp=2; IntAct=EBI-6895930, EBI-297353; CC P07948-1; P33993: MCM7; NbExp=5; IntAct=EBI-6895930, EBI-355924; CC -!- SUBCELLULAR LOCATION: Cell membrane. Nucleus. Cytoplasm. Cytoplasm, CC perinuclear region. Golgi apparatus. Membrane {ECO:0000305}; Lipid- CC anchor {ECO:0000305}. Note=Accumulates in the nucleus by inhibition of CC CRM1-mediated nuclear export. Nuclear accumulation is increased by CC inhibition of its kinase activity. The trafficking from the Golgi CC apparatus to the plasma membrane occurs in a kinase domain-dependent CC but kinase activity independent manner and is mediated by exocytic CC vesicular transport. Detected on plasma membrane lipid rafts. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=LYN A, p56lyn; CC IsoId=P07948-1; Sequence=Displayed; CC Name=2; Synonyms=LYN B, p53lyn; CC IsoId=P07948-2; Sequence=VSP_005002; CC -!- TISSUE SPECIFICITY: Detected in monocytes (at protein level). Detected CC in placenta, and in fetal brain, lung, liver and kidney. Widely CC expressed in a variety of organs, tissues, and cell types such as CC epidermoid, hematopoietic, and neuronal cells. Expressed in primary CC neuroblastoma tumors. {ECO:0000269|PubMed:3561390, CC ECO:0000269|PubMed:8064233}. CC -!- DOMAIN: The protein kinase domain plays an important role in its CC localization in the cell membrane. {ECO:0000269|PubMed:15173188}. CC -!- PTM: Ubiquitinated by CBL, leading to its degradation. Ubiquitination CC is SH3-dependent. {ECO:0000269|PubMed:16920712, CC ECO:0000269|PubMed:20534535}. CC -!- PTM: Autophosphorylated (PubMed:7935444, PubMed:9171348, CC PubMed:9341198, PubMed:18056483, PubMed:18070987). Phosphorylated on CC tyrosine residues in response to KIT signaling (PubMed:9341198). CC Phosphorylation at Tyr-397 is required for optimal activity CC (PubMed:16920712). Phosphorylation at Tyr-508 inhibits kinase activity CC (PubMed:9171348). Phosphorylated at Tyr-508 by CSK (PubMed:7935444). CC Dephosphorylated by PTPRC/CD45 (By similarity). Becomes rapidly CC phosphorylated upon activation of the B-cell receptor and the CC immunoglobulin receptor FCGR1A (PubMed:8064233). Phosphorylated in CC response to ITGB1 in B-cells (PubMed:9020138). CC {ECO:0000250|UniProtKB:P25911, ECO:0000269|PubMed:16920712, CC ECO:0000269|PubMed:18056483, ECO:0000269|PubMed:18070987, CC ECO:0000269|PubMed:7935444, ECO:0000269|PubMed:8064233, CC ECO:0000269|PubMed:9020138, ECO:0000269|PubMed:9171348, CC ECO:0000269|PubMed:9341198}. CC -!- DISEASE: Autoinflammatory disease, systemic, with vasculitis (SAIDV) CC [MIM:620376]: An autosomal dominant disorder characterized by systemic CC autoinflammation manifesting in the first hours of life with diffuse CC purpuric skin lesions, fever, hepatosplenomegaly, and increased C- CC reactive protein. Additional clinical features include periorbital CC edema, conjunctivitis, urticaria, atopic dermatitis, abdominal pain, CC and arthralgia. Laboratory studies may show leukocytosis, CC thrombocytopenia, and autoantibodies. {ECO:0000269|PubMed:16920712, CC ECO:0000269|PubMed:36122175, ECO:0000269|PubMed:36932076, CC ECO:0000269|Ref.67}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Note=Constitutively phosphorylated and activated in cells from CC a number of chronic myelogenous leukemia (CML) and acute myeloid CC leukemia (AML) patients. Mediates phosphorylation of the BCR-ABL fusion CC protein. Abnormally elevated expression levels or activation of LYN CC signaling may play a role in survival and proliferation of some types CC of cancer cells. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. SRC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M16038; AAA59540.1; -; mRNA. DR EMBL; M79321; AAB50019.1; -; mRNA. DR EMBL; BC075001; AAH75001.1; -; mRNA. DR EMBL; BC075002; AAH75002.1; -; mRNA. DR EMBL; BC126456; AAI26457.1; -; mRNA. DR EMBL; BC126458; AAI26459.1; -; mRNA. DR CCDS; CCDS47859.1; -. [P07948-2] DR CCDS; CCDS6162.1; -. [P07948-1] DR PIR; A26719; TVHULY. DR RefSeq; NP_001104567.1; NM_001111097.2. [P07948-2] DR RefSeq; NP_002341.1; NM_002350.3. [P07948-1] DR RefSeq; XP_016868905.1; XM_017013416.1. DR PDB; 1W1F; NMR; -; A=61-123. DR PDB; 1WA7; NMR; -; A=61-123. DR PDB; 3A4O; X-ray; 3.00 A; X=233-512. DR PDB; 5XY1; X-ray; 2.70 A; A=239-512. DR PDB; 6NMW; X-ray; 1.20 A; A=63-125. DR PDB; 8WFF; X-ray; 1.30 A; A=63-125. DR PDBsum; 1W1F; -. DR PDBsum; 1WA7; -. DR PDBsum; 3A4O; -. DR PDBsum; 5XY1; -. DR PDBsum; 6NMW; -. DR PDBsum; 8WFF; -. DR AlphaFoldDB; P07948; -. DR BMRB; P07948; -. DR SMR; P07948; -. DR BioGRID; 110245; 729. DR CORUM; P07948; -. DR DIP; DIP-1056N; -. DR ELM; P07948; -. DR IntAct; P07948; 144. DR MINT; P07948; -. DR STRING; 9606.ENSP00000428924; -. DR BindingDB; P07948; -. DR ChEMBL; CHEMBL3905; -. DR DrugBank; DB03023; 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine. DR DrugBank; DB06616; Bosutinib. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB08901; Ponatinib. DR DrugCentral; P07948; -. DR GuidetoPHARMACOLOGY; 2060; -. DR iPTMnet; P07948; -. DR PhosphoSitePlus; P07948; -. DR SwissPalm; P07948; -. DR BioMuta; LYN; -. DR DMDM; 125480; -. DR REPRODUCTION-2DPAGE; P07948; -. DR CPTAC; CPTAC-2785; -. DR EPD; P07948; -. DR jPOST; P07948; -. DR MassIVE; P07948; -. DR MaxQB; P07948; -. DR PaxDb; 9606-ENSP00000428924; -. DR PeptideAtlas; P07948; -. DR ProteomicsDB; 52045; -. [P07948-1] DR ProteomicsDB; 52046; -. [P07948-2] DR Pumba; P07948; -. DR Antibodypedia; 51187; 1038 antibodies from 45 providers. DR DNASU; 4067; -. DR Ensembl; ENST00000519728.6; ENSP00000428924.1; ENSG00000254087.8. [P07948-1] DR Ensembl; ENST00000520220.6; ENSP00000428424.1; ENSG00000254087.8. [P07948-2] DR GeneID; 4067; -. DR KEGG; hsa:4067; -. DR MANE-Select; ENST00000519728.6; ENSP00000428924.1; NM_002350.4; NP_002341.1. DR UCSC; uc003xsk.5; human. [P07948-1] DR AGR; HGNC:6735; -. DR CTD; 4067; -. DR DisGeNET; 4067; -. DR GeneCards; LYN; -. DR HGNC; HGNC:6735; LYN. DR HPA; ENSG00000254087; Tissue enhanced (bone marrow, lymphoid tissue). DR MalaCards; LYN; -. DR MIM; 165120; gene. DR MIM; 620376; phenotype. DR neXtProt; NX_P07948; -. DR OpenTargets; ENSG00000254087; -. DR PharmGKB; PA30498; -. DR VEuPathDB; HostDB:ENSG00000254087; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000158011; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; P07948; -. DR OMA; TGNMGCI; -. DR OrthoDB; 1614410at2759; -. DR PhylomeDB; P07948; -. DR TreeFam; TF351634; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P07948; -. DR Reactome; R-HSA-114604; GPVI-mediated activation cascade. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-1433559; Regulation of KIT signaling. DR Reactome; R-HSA-202733; Cell surface interactions at the vascular wall. DR Reactome; R-HSA-2029481; FCGR activation. DR Reactome; R-HSA-210990; PECAM1 interactions. DR Reactome; R-HSA-2454202; Fc epsilon receptor (FCERI) signaling. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization. DR Reactome; R-HSA-2871837; FCERI mediated NF-kB activation. DR Reactome; R-HSA-389356; CD28 co-stimulation. DR Reactome; R-HSA-389513; CTLA4 inhibitory signaling. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR Reactome; R-HSA-5621480; Dectin-2 family. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5690714; CD22 mediated BCR regulation. DR Reactome; R-HSA-69231; Cyclin D associated events in G1. DR Reactome; R-HSA-75892; Platelet Adhesion to exposed collagen. DR Reactome; R-HSA-9006335; Signaling by Erythropoietin. DR Reactome; R-HSA-9027276; Erythropoietin activates Phosphoinositide-3-kinase (PI3K). DR Reactome; R-HSA-9027277; Erythropoietin activates Phospholipase C gamma (PLCG). DR Reactome; R-HSA-9027283; Erythropoietin activates STAT5. DR Reactome; R-HSA-9027284; Erythropoietin activates RAS. DR Reactome; R-HSA-912631; Regulation of signaling by CBL. DR Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis. DR Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9674555; Signaling by CSF3 (G-CSF). DR Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells. DR Reactome; R-HSA-9705462; Inactivation of CSF3 (G-CSF) signaling. DR Reactome; R-HSA-982772; Growth hormone receptor signaling. DR Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers. DR SignaLink; P07948; -. DR SIGNOR; P07948; -. DR BioGRID-ORCS; 4067; 24 hits in 1216 CRISPR screens. DR ChiTaRS; LYN; human. DR EvolutionaryTrace; P07948; -. DR GeneWiki; LYN; -. DR GenomeRNAi; 4067; -. DR Pharos; P07948; Tclin. DR PRO; PR:P07948; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; P07948; Protein. DR Bgee; ENSG00000254087; Expressed in monocyte and 189 other cell types or tissues. DR ExpressionAtlas; P07948; baseline and differential. DR GO; GO:0005912; C:adherens junction; IEA:Ensembl. DR GO; GO:0009986; C:cell surface; IDA:UniProt. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProt. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0034666; C:integrin alpha2-beta1 complex; IEA:Ensembl. DR GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA. DR GO; GO:0005765; C:lysosomal membrane; TAS:Reactome. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0030061; C:mitochondrial crista; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0099091; C:postsynaptic specialization, intracellular component; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0046875; F:ephrin receptor binding; IPI:ARUK-UCL. DR GO; GO:0043015; F:gamma-tubulin binding; IEA:Ensembl. DR GO; GO:0043208; F:glycosphingolipid binding; IEA:Ensembl. DR GO; GO:0005178; F:integrin binding; IEA:Ensembl. DR GO; GO:0016301; F:kinase activity; NAS:ARUK-UCL. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IMP:ARUK-UCL. DR GO; GO:0141038; F:phosphatidylinositol 3-kinase activator activity; IEA:Ensembl. DR GO; GO:0051219; F:phosphoprotein binding; IEA:Ensembl. DR GO; GO:0140031; F:phosphorylation-dependent protein binding; IPI:UniProtKB. DR GO; GO:0005161; F:platelet-derived growth factor receptor binding; IEA:Ensembl. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0097110; F:scaffold protein binding; IPI:ARUK-UCL. DR GO; GO:0017124; F:SH3 domain binding; IEA:Ensembl. DR GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central. DR GO; GO:0044325; F:transmembrane transporter binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0001782; P:B cell homeostasis; ISS:UniProtKB. DR GO; GO:0050853; P:B cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0038159; P:C-X-C chemokine receptor CXCR4 signaling pathway; IMP:UniProtKB. DR GO; GO:0031668; P:cellular response to extracellular stimulus; IEA:Ensembl. DR GO; GO:0034605; P:cellular response to heat; IEA:Ensembl. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0097028; P:dendritic cell differentiation; ISS:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030222; P:eosinophil differentiation; IDA:UniProt. DR GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome. DR GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB. DR GO; GO:0002774; P:Fc receptor mediated inhibitory signaling pathway; ISS:UniProtKB. DR GO; GO:0002431; P:Fc receptor mediated stimulatory signaling pathway; ISS:UniProtKB. DR GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome. DR GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome. DR GO; GO:0060397; P:growth hormone receptor signaling pathway via JAK-STAT; TAS:Reactome. DR GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB. DR GO; GO:0002553; P:histamine secretion by mast cell; IEA:Ensembl. DR GO; GO:0002768; P:immune response-regulating cell surface receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0045087; P:innate immune response; IBA:GO_Central. DR GO; GO:0038043; P:interleukin-5-mediated signaling pathway; IDA:UniProt. DR GO; GO:0035556; P:intracellular signal transduction; IEA:Ensembl. DR GO; GO:0050900; P:leukocyte migration; TAS:Reactome. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; ISS:UniProtKB. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IBA:GO_Central. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0050777; P:negative regulation of immune response; TAS:UniProtKB. DR GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome. DR GO; GO:1902532; P:negative regulation of intracellular signal transduction; ISS:UniProtKB. DR GO; GO:0043407; P:negative regulation of MAP kinase activity; ISS:UniProtKB. DR GO; GO:0070667; P:negative regulation of mast cell proliferation; ISS:UniProtKB. DR GO; GO:0002762; P:negative regulation of myeloid leukocyte differentiation; IEA:Ensembl. DR GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:UniProtKB. DR GO; GO:0034136; P:negative regulation of toll-like receptor 2 signaling pathway; ISS:UniProtKB. DR GO; GO:0034144; P:negative regulation of toll-like receptor 4 signaling pathway; ISS:UniProtKB. DR GO; GO:0031175; P:neuron projection development; IBA:GO_Central. DR GO; GO:0014003; P:oligodendrocyte development; IEA:Ensembl. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0002576; P:platelet degranulation; ISS:UniProtKB. DR GO; GO:1902961; P:positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process; IMP:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB. DR GO; GO:2000670; P:positive regulation of dendritic cell apoptotic process; ISS:UniProtKB. DR GO; GO:0060369; P:positive regulation of Fc receptor mediated stimulatory signaling pathway; IEA:Ensembl. DR GO; GO:0060252; P:positive regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:0070668; P:positive regulation of mast cell proliferation; IMP:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0070447; P:positive regulation of oligodendrocyte progenitor proliferation; IEA:Ensembl. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IGI:ARUK-UCL. DR GO; GO:0070304; P:positive regulation of stress-activated protein kinase signaling cascade; IDA:UniProtKB. DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0002902; P:regulation of B cell apoptotic process; IBA:GO_Central. DR GO; GO:0050855; P:regulation of B cell receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; IMP:UniProtKB. DR GO; GO:0001817; P:regulation of cytokine production; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0045646; P:regulation of erythrocyte differentiation; ISS:UniProtKB. DR GO; GO:0033003; P:regulation of mast cell activation; ISS:UniProtKB. DR GO; GO:0043304; P:regulation of mast cell degranulation; ISS:UniProtKB. DR GO; GO:0090025; P:regulation of monocyte chemotaxis; IMP:UniProtKB. DR GO; GO:0090330; P:regulation of platelet aggregation; ISS:UniProtKB. DR GO; GO:0001932; P:regulation of protein phosphorylation; TAS:UniProtKB. DR GO; GO:0051279; P:regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl. DR GO; GO:0043200; P:response to amino acid; IEA:Ensembl. DR GO; GO:0048678; P:response to axon injury; IEA:Ensembl. DR GO; GO:0009743; P:response to carbohydrate; IEA:Ensembl. DR GO; GO:0009725; P:response to hormone; ISS:UniProtKB. DR GO; GO:0032868; P:response to insulin; IEA:Ensembl. DR GO; GO:0014070; P:response to organic cyclic compound; IEA:Ensembl. DR GO; GO:0006991; P:response to sterol depletion; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0002513; P:tolerance induction to self antigen; ISS:UniProtKB. DR GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IEA:Ensembl. DR GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IMP:UniProtKB. DR CDD; cd05072; PTKc_Lyn; 1. DR CDD; cd10364; SH2_Src_Lyn; 1. DR CDD; cd12004; SH3_Lyn; 1. DR DisProt; DP02545; -. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00701; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR035852; Lyn_SH2. DR InterPro; IPR035748; Lyn_SH3. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR PANTHER; PTHR24418:SF42; TYROSINE-PROTEIN KINASE LYN; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. DR Genevisible; P07948; HS. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; Alternative splicing; ATP-binding; KW Cell membrane; Cytoplasm; Disease variant; Golgi apparatus; KW Host-virus interaction; Immunity; Inflammatory response; Innate immunity; KW Kinase; Lipoprotein; Membrane; Myristate; Nucleotide-binding; Nucleus; KW Palmitate; Phosphoprotein; Proto-oncogene; Reference proteome; SH2 domain; KW SH3 domain; Transferase; Tyrosine-protein kinase; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:25255805" FT CHAIN 2..512 FT /note="Tyrosine-protein kinase Lyn" FT /id="PRO_0000088129" FT DOMAIN 63..123 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 129..226 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 247..501 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..62 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 23..55 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 367 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 253..261 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 275 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 11 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 13 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 193 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:18577747" FT MOD_RES 228 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 306 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 316 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 397 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18070987, FT ECO:0000269|PubMed:7935444" FT MOD_RES 460 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:18577747" FT MOD_RES 473 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 508 FT /note="Phosphotyrosine; by autocatalysis, CSK and MATK" FT /evidence="ECO:0000269|PubMed:18070987, FT ECO:0000269|PubMed:7935444, ECO:0000269|PubMed:9171348, FT ECO:0007744|PubMed:15592455, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT LIPID 2 FT /note="N-myristoyl glycine" FT /evidence="ECO:0000269|PubMed:25255805, FT ECO:0000305|PubMed:18817770" FT LIPID 3 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:18817770" FT VAR_SEQ 23..43 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:8125304" FT /id="VSP_005002" FT VARIANT 385 FT /note="D -> Y (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041737" FT VARIANT 507..512 FT /note="Missing (in SAIDV; pathogenic; increased kinase FT activity due to loss of autoinhibition resulting in FT constitutive activation; loss of Y-508 phosphorylation; FT increased Y-397 phosphorylation)" FT /evidence="ECO:0000269|PubMed:36932076" FT /id="VAR_088619" FT VARIANT 508..512 FT /note="Missing (in SAIDV; pathogenic; increased kinase FT activity due to loss of autoinhibition resulting in FT constitutive activation; loss of Y-508 phosphorylation; FT increased Y-397 phosphorylation)" FT /evidence="ECO:0000269|PubMed:36122175, FT ECO:0000269|PubMed:36932076, ECO:0000269|Ref.67" FT /id="VAR_088620" FT VARIANT 508 FT /note="Y -> F (in SAIDV; pathogenic; increased kinase FT activity due to loss of autoinhibition resulting in FT constitutive activation; loss of Y-508 phosphorylation; FT increased Y-397 phosphorylation)" FT /evidence="ECO:0000269|PubMed:16920712, FT ECO:0000269|PubMed:36122175, ECO:0000269|PubMed:36932076" FT /id="VAR_088621" FT VARIANT 508 FT /note="Y -> H (in SAIDV; pathogenic; increased kinase FT activity due to loss of autoinhibition resulting in FT constitutive activation; loss of Y-508 phosphorylation; FT increased Y-397 phosphorylation)" FT /evidence="ECO:0000269|PubMed:36122175" FT /id="VAR_088622" FT MUTAGEN 2 FT /note="G->A: Loss of localization to the cell membrane; FT when associated with A-3." FT /evidence="ECO:0000269|PubMed:18817770" FT MUTAGEN 3 FT /note="C->A: Loss of localization to the cell membrane; FT when associated with A-2." FT /evidence="ECO:0000269|PubMed:18817770" FT MUTAGEN 275 FT /note="K->A: Loss of activity and no effect on localization FT to the cell membrane. Abundant localization in the nucleus; FT when associated with A-2 and A-3." FT /evidence="ECO:0000269|PubMed:11435302, FT ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:15173188, FT ECO:0000269|PubMed:18817770" FT MUTAGEN 275 FT /note="K->L,R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11435302, FT ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:15173188, FT ECO:0000269|PubMed:18817770" FT MUTAGEN 346 FT /note="D->A: Impedes the trafficking from the Golgi FT apparatus toward the cell membrane; when associated with FT A-353; A-498 and A-499." FT /evidence="ECO:0000269|PubMed:15173188" FT MUTAGEN 353 FT /note="E->A: Impedes the trafficking from the Golgi FT apparatus toward the cell membrane; when associated with FT A-346; A-498 and A-499." FT /evidence="ECO:0000269|PubMed:15173188" FT MUTAGEN 397 FT /note="Y->F: Strongly reduced kinase activity." FT /evidence="ECO:0000269|PubMed:16920712" FT MUTAGEN 498 FT /note="D->A: Impedes the trafficking from the Golgi FT apparatus toward the cell membrane; when associated with FT A-346; A-353 and A-499." FT /evidence="ECO:0000269|PubMed:15173188" FT MUTAGEN 499 FT /note="D->A: Impedes the trafficking from the Golgi FT apparatus toward the cell membrane; when associated with FT A-346; A-353 and A-498." FT /evidence="ECO:0000269|PubMed:15173188" FT STRAND 67..72 FT /evidence="ECO:0007829|PDB:6NMW" FT STRAND 78..80 FT /evidence="ECO:0007829|PDB:1W1F" FT STRAND 89..96 FT /evidence="ECO:0007829|PDB:6NMW" FT STRAND 99..104 FT /evidence="ECO:0007829|PDB:6NMW" FT TURN 105..107 FT /evidence="ECO:0007829|PDB:6NMW" FT STRAND 110..114 FT /evidence="ECO:0007829|PDB:6NMW" FT HELIX 115..117 FT /evidence="ECO:0007829|PDB:6NMW" FT STRAND 118..121 FT /evidence="ECO:0007829|PDB:6NMW" FT HELIX 244..246 FT /evidence="ECO:0007829|PDB:5XY1" FT STRAND 247..255 FT /evidence="ECO:0007829|PDB:5XY1" FT STRAND 260..266 FT /evidence="ECO:0007829|PDB:5XY1" FT TURN 267..269 FT /evidence="ECO:0007829|PDB:5XY1" FT STRAND 270..277 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 284..296 FT /evidence="ECO:0007829|PDB:5XY1" FT STRAND 305..309 FT /evidence="ECO:0007829|PDB:5XY1" FT STRAND 311..320 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 327..332 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 334..338 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 341..360 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 370..372 FT /evidence="ECO:0007829|PDB:5XY1" FT STRAND 373..375 FT /evidence="ECO:0007829|PDB:5XY1" FT STRAND 381..383 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 407..409 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 412..417 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 422..437 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 449..457 FT /evidence="ECO:0007829|PDB:5XY1" FT STRAND 466..468 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 470..479 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 484..486 FT /evidence="ECO:0007829|PDB:5XY1" FT HELIX 490..501 FT /evidence="ECO:0007829|PDB:5XY1" SQ SEQUENCE 512 AA; 58574 MW; 408D3D461204E378 CRC64; MGCIKSKGKD SLSDDGVDLK TQPVRNTERT IYVRDPTSNK QQRPVPESQL LPGQRFQTKD PEEQGDIVVA LYPYDGIHPD DLSFKKGEKM KVLEEHGEWW KAKSLLTKKE GFIPSNYVAK LNTLETEEWF FKDITRKDAE RQLLAPGNSA GAFLIRESET LKGSFSLSVR DFDPVHGDVI KHYKIRSLDN GGYYISPRIT FPCISDMIKH YQKQADGLCR RLEKACISPK PQKPWDKDAW EIPRESIKLV KRLGAGQFGE VWMGYYNNST KVAVKTLKPG TMSVQAFLEE ANLMKTLQHD KLVRLYAVVT REEPIYIITE YMAKGSLLDF LKSDEGGKVL LPKLIDFSAQ IAEGMAYIER KNYIHRDLRA ANVLVSESLM CKIADFGLAR VIEDNEYTAR EGAKFPIKWT APEAINFGCF TIKSDVWSFG ILLYEIVTYG KIPYPGRTNA DVMTALSQGY RMPRVENCPD ELYDIMKMCW KEKAEERPTF DYLQSVLDDF YTATEGQYQQ QP //